losartan-potassium and Exophthalmos

losartan-potassium has been researched along with Exophthalmos* in 1 studies

Other Studies

1 other study(ies) available for losartan-potassium and Exophthalmos

Article	Year
Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone. WMJ : official publication of the State Medical Society of Wisconsin, 2009, Volume: 108, Issue:9 Thiazolidinediones (TZDs) are frequently used pharmacotherapeutics for type II diabetes mellitus, which exert their effect through peroxisomal proliferator agonist receptor (PPAR) mediated increased insulin sensitivity. TZDs are known to cause marrow suppression and to stimulate adipogenesis. Case and cohort studies show TZDs worsen thyroid-associated orbitopathy. We present a case consistent with earlier reports of marrow suppressive pancytopenia manifesting as myelodysplastic syndrome, a new implication of hypoerythropoetinemia, and non-Graves'-associated proliferative proptosis. Topics: Diabetes Mellitus, Type 2; Erythropoietin; Exophthalmos; Female; Humans; Hypoglycemic Agents; Lipodystrophy; Middle Aged; Myelodysplastic Syndromes; Rosiglitazone; Thiazolidinediones	2009

Article

Year

Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone.

WMJ : official publication of the State Medical Society of Wisconsin, 2009, Volume: 108, Issue:9

Thiazolidinediones (TZDs) are frequently used pharmacotherapeutics for type II diabetes mellitus, which exert their effect through peroxisomal proliferator agonist receptor (PPAR) mediated increased insulin sensitivity. TZDs are known to cause marrow suppression and to stimulate adipogenesis. Case and cohort studies show TZDs worsen thyroid-associated orbitopathy. We present a case consistent with earlier reports of marrow suppressive pancytopenia manifesting as myelodysplastic syndrome, a new implication of hypoerythropoetinemia, and non-Graves'-associated proliferative proptosis.

Topics: Diabetes Mellitus, Type 2; Erythropoietin; Exophthalmos; Female; Humans; Hypoglycemic Agents; Lipodystrophy; Middle Aged; Myelodysplastic Syndromes; Rosiglitazone; Thiazolidinediones

2009